Interim results from DIAGNODE-1 indicate clear and desired

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Interim results from DIAGNODE-1 indicate clear and desired re-balancing of the immune system after administration of Diamyd® directly into lymph nodes

Diamyd Medical (Nasdaq Stockholm First North, Ticker: DMYD B) today announced that Professor Johnny Ludvigsson will present preliminary immunological interim results from four patients in the pilot study DIAGNODE-1 at the diabetes meeting SSSD in Reykjavik 21-22 April. The interim results indicate that administration of a low dose of the diabetes vaccine Diamyd® in lymph glands clearly re -balances the immune system towards a desired so called Th2 response. As previously reported, the treatment appears to be safe and tolerable and the clinical progression seems positive. It is however too early to draw any conclusions in these few patients. As previously communicated, Professor Johnny Ludvigsson, principal investigator and sponsor of DIAGNODE-1, will present a first preliminary evaluation of data from the first four patients that have been monitored for six months in the study at the diabetes meeting “51st Annual Meeting of the Scandinavian Society for the Study of Diabetes (SSSD)” which is held in Reykjavik, Iceland, on April 21-22, 2016. As previously reported, this evaluation preliminarily shows that the treatment appears to be safe and tolerable and that the clinical progression shows certain positive data in terms of the body’s own capacity to produce insulin, as well as better long-term blood sugar and lower insulin dose, even if no conclusions can be drawn in these few patients who still may be in the so called honeymoon-phase, often characterized by some regression of the disease. Professor Ludvigsson with team have now also evaluated immunological markers, which indicate that the diabetes vaccine Diamyd®administered directly into lymph nodes generates a clear and desired immune deviation. Here, the so called Th1 response – which is associated with the autoimmunity in type 1 diabetes – is skewed towards a so called Th2 response, which is the desired immunological response when aiming to preserve endogen insulin secretion. This is shown by the relative secretion of cytokines where, upon the immune system’s contact with GAD65, a larger concentration of for example IL-13 is observed compared to IFN -gamma. A pronounced increase in GAD antibodies can also be seen in the four patients. ”These are promising preliminary results,” says Professor Johnny Ludvigsson, principal investigator and sponsor of the study. “Next step of the immunological analyses is to compare this response with other ongoing studies where the GAD vaccine is administrated subcutaneously, with the aim of determining how different modes of administration of GAD affect the immune response and also to see if the observed immunological effect correlates with clinical effect.” ”The possibility to analyze explorative data from the six ongoing clinical studies with the diabetes vaccine Diamyd® is an important component of Diamyd Medical’s strategy,” says Ulf Hannelius, President and CEO of Diamyd Medical. “We are continuously evaluating the potential of our treatment regime on the basis of all collected data to be able to, in the best way possible, take the next step towards the market.” The pilot study DIAGNODE-1 is the first study of its kind, where a low dose of Diamyd® is administered directly into lymph nodes in combination with treatment with vitamin D. The concept, for which Diamyd Medical has submitted a patent application, can be compared to the development in allergy therapy, where the administration of allergen into lymph nodes has significantly improved efficacy, while concurrently decreasing the dose. Vitamin D is provided in order to down regulate the immune system’s inflammatory components to thereby increase the diabetes vaccine’s tolerance inducing effect with the aim of preserving the patient’s insulin producing capacity. DIAGNODE-1 is an open pilot study which comprises a total of nine patients between the ages of 12 and 30 who have been diagnosed with type 1 diabetes in the past six months. The patients are monitored for 30 months. All participants are given a low dose (4µg) of Diamyd® into a lymph node on three occasions, in combination with intake of vitamin D. About Diamyd® and combination trials Type 1 diabetes is a devastating disease which requires daily treatment with insulin to sustain life. The importance of finding a cure should not be underestimated. The diabetes vaccine Diamyd® has been used in clinical studies with more than 1,000 patients and has shown a good safety profile. In a European Phase III trial Diamyd® showed good clinical effect in several subgroups, and a limited overall 16% efficacy (p=0.10) in preserving endogenous insulin secretion. Subsequent development is focused on combination trials to enhance efficacy. Diamyd® is easy to administer in any clinical setting. The potential annual market is estimated to several billion dollars per year. Six researcher initiated clinical trials are ongoing combining Diamyd® with various other immunomodulatory compounds; etanercept, ibuprofen, vitamin D and GABA. · DIABGAD-1 – COMBINING DIAMYD® WITH IBUPROFEN AND VITAMIN D A placebo-controlled trial, where Diamyd® is being tested in combination with ibuprofen and vitamin D. The trial comprises a total of 64 patients between the ages of 10 and 18, recently diagnosed with type 1 diabetes, and will continue for a total of 30 months. The aim of the combination treatment is to preserve the body’s own capacity to produce insulin. The trial runs at nine clinics in Sweden and is led by Professor Johnny Ludvigsson at Linköping University, Sweden. 30 month results from the trial are due during the first half year of 2017. · DIAGNODE-1 –DIAMYD® IN LYMPH GLANDS IN COMBINATION WITH VITAMIN D An open label trial, where Diamyd® is administered directly into lymph nodes in combination with treatment with vitamin D. The trial comprises nine patients between the ages of 12 and 30 newly diagnosed with type 1 diabetes, and will continue for a total of 30 months. The aim of the trial is to evaluate the safety of the combination treatment and the effect on the immune system and the patients’ insulin producing capacity. The trial is led by Professor Johnny Ludvigsson at Linköping University, Sweden. The first patient was included in the trial in February 2015. · GABA/DIAMYD® – COMBINING DIAMYD® WITH GABA A placebo-controlled trial, where Diamyd® is being tested in combination with GABA. The trial comprises 75 patients between the ages of 4 and 18 recently diagnosed with type 1 diabetes, and will continue for a total of 12 months. The aim of the combination treatment is to preserve the body’s residual capacity to produce insulin. The trial is led by Professor Kenneth McCormick at the University of Alabama at Birmingham, USA. The first patient was included in the trial in March 2015. · EDCR IIa – COMBINING DIAMYD® WITH ETANERCEPT AND VITAMIN D An open label trial, where Diamyd® is combined with etanercept and vitamin D. The trial comprises 20 patients between the ages of 8 and 18 who have been newly diagnosed with type 1 diabetes, and will continue for a total of 30 months. The aim of the trial is to evaluate the safety of the combination treatment and the effect on the immune system and the patients’ insulin producing capacity. The trial is led by Professor Johnny Ludvigsson at Linköping University, Sweden. The first patient was included in May 2015. · DiAPREV-IT 1– DIAMYD® A placebo-controlled trial, where Diamyd® is being tested in children at high risk of developing type 1 diabetes, meaning that they have been found to have an ongoing autoimmune process but do not yet have any clinical symptoms of diabetes. A total of 50 participants from the age of four have been enrolled in the trial, which will last for five years. The aim of the trial is to evaluate whether Diamyd® can delay or prevent the participants from presenting with type 1 diabetes. The trial is led by Dr. Helena Elding Larsson at Lund University, Sweden. Five year results are expected at the end of 2016. · DiAPREV-IT 2 – COMBINING DIAMYD® WITH VITAMIN D A placebo-controlled trial, where Diamyd® is being tested in combination with vitamin D in children at high risk of developing type 1 diabetes, meaning that they have been found to have an ongoing autoimmune process but do not yet have any clinical symptoms of diabetes. A total of 80 participants between the ages of 4 and 18 will be enrolled in the trial, which will last for five years. The aim of the trial is to evaluate whether Diamyd® can delay or prevent the participants from presenting with type 1 diabetes. The trial is led by Dr. Helena Elding Larsson at Lund University, Sweden. The first patient was included in March 2015. About Diamyd Medical Diamyd Medical is dedicated to finding a cure for autoimmune diabetes through pharmaceutical development and investments in stem cell and medical technology. Diamyd Medical develops the diabetes vaccine Diamyd®, an Antigen Based Therapy (ABT) based on the exclusively licensed GAD-molecule. The Company’s licensed technologies for GABA and Gliadin have also potential to become key pieces of the puzzle of a future solution to prevent, treat or cure autoimmune diabetes, and also certain inflammatory diseases. At this time six clinical studies are ongoing with Diamyd®. Diamyd Medical is with its holdings of 45% one of the major shareholders in the stem cell company Cellaviva AB. Stem cells can be expected to be used in Personalized Regenerative Medicine (PRM), for example for restoration of beta cell mass in diabetes patients where the autoimmune component of the disease has been arrested. Diamyd Medical also has holdings in the medtech company Companion Medical, Inc., San Diego, USA and in the gene therapy company Periphagen, Inc., Pittsburgh, USA. Diamyd Medical’s B-share is traded on Nasdaq Stockholm First North under the ticker DMYD B. Remium Nordic AB is the Company’s Certified Adviser. For further information, please contact: Ulf Hannelius, President and CEO Phone: +46 736 35 42 41. E-mail: ulf.hannelius@diamyd.com Diamyd Medical AB (publ) Kungsgatan 29, SE-111 56 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8 661 63 68 E-mail: info@diamyd.com. Reg. no.: 556242-3797. Website: www.diamyd.com.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CD Rates Offer Stillness as Stocks and Gold Wobble

Updated Category News Views 16

November has delivered the sort of tape that makes a supposedly diversified portfolio feel like a leaky boat. Stocks fell sharply, gold slid to a one-year low after record highs as recently as January, and Treasuries have not provided the dependable ballast many investors expected. When inflation worries and federal-debt concerns shove yields higher, bond prices can drop...

Continue Reading
Cracking Life Insurance Needs: John Dorsa's Insights

Updated Category News Views 150

Life Insurance: A Necessary Puzzle Life’s uncertainties have a way of putting a wrench in our plans, and nothing screams uncertainty like figuring out life insurance. But fret not! HelloNation’s got insights on this financial maze, and they’ve roped in insurance pro John Dorsa from Ridgeland to help out. Calculating Coverage Needs Forget the one-size-fits-all...

Continue Reading
CSMI Boosts CT's Cybersecurity for Defense Sector

Updated Category News Views 132

Paving the Way for Cybersecurity Excellence Out in chilly Connecticut, CSMI made a mark. The State's Office of Manufacturing picked them to join the advisory council for the Defense CyberSecure Program (CT-DCP). It ain’t just a pat on the back; it's a big deal for the region's defense and aerospace manufacturing gang. Connecticut's got its eyes set on beefing up its...

Continue Reading
Biotech Hit or Miss: Trials and Tribulations

Updated Category News Views 127

Biotech's Roller Coaster: Triumphs and Setbacks Ah, the biotech sector—it's a bit like jumping on a bull, ain't it? You barely hang on when the beast bucks. Monday's market action was downright wild. The S&P 500 didn't have a party, tumbling 1.92%, and the Nasdaq wasn't any friendlier, plummeting 2.49%. Yet, inside this storm, we see some biotech names either catching...

Continue Reading
NVCA Refreshes Key Venture Legal Documents for 2026

Updated Category News Views 115

Keeping Pace with Evolving Venture Norms Change never lets up in the fast-paced world of venture capital, does it? Just when you think you've got the rules figured out, the game shifts. This time, it's the National Venture Capital Association (NVCA) shaking things up. They've given a facelift to seven of their model legal documents, a move that reshapes the legal...

Continue Reading
GALC Launches Tender Offer on 2027 Notes Amid Debt Play

Updated Category News Views 91

Aviation Leasing Giant's Strategic Financial Move Well folks, we're staring down the barrel of a financial maneuver by Global Aircraft Leasing Co., Ltd. (GALC) that’s not just another day at the office. They've kicked off a cash tender offer for their 8.750% Senior Secured Notes due 2027, aiming to sweep up any and all outstanding ones. That's $932 million in principle...

Continue Reading
TYYY Liquidation Leaves Holders With a Tight Exit Window

Updated Category News Views 28

A fund can vanish faster than investors can read the fine print, and TYYY is doing exactly that. Exchange Traded Concepts has approved the closure and liquidation of the xETFs TSLA Daily Income ETF, with the fund expected to cease operations and distribute cash on or about November 20, 2026. This is not a debate about whether holders should love or hate Tesla. The product...

Continue Reading
Stellus PBDC's Q3: Solid Income but NAV Drops

Updated Category News Views 208

Stellus PBDC: Q3 Earnings and Strategic Moves Things are getting interesting in Houston where Stellus Private Credit BDC just laid out its financial cards for the third quarter of 2026. Now, I’ve seen my fair share of quarterly reports, but Stellus seems to have stitched a quilt of mixed results this time around. Investment Income and Portfolio Shifts First off, net...

Continue Reading
PawnMate Boosts Inventory Efficiency for Pawnshops

Updated Category News Views 213

RFID Technology: Breathing New Life into Pawnshops Let's get things rolling with the cold, hard truth that pawnshops aren't exactly what most folks expect when it comes to cutting-edge technology. But times are a-changin', and PawnMate’s RFID Inventory Module is the latest twist in this industry storyline. It's like swapping out a rusty toolbox for a brand-new set of...

Continue Reading
Fuel Cell Market Faces Uneven Growth Amid Revenue Shifts

Updated Category News Views 144

Fuel Cell Sector Eyes Mixed Results and Big Projections The fuel cell market, oh what a beast it's becoming—a story filled with ups and downs, and more forecasts than a weather station. As we stand, this sector is poised to balloon to an $18.16 billion market by 2030. That's a growth rate of 26.3% annually, folks. These projections are driving excitement, but the...

Continue Reading

Top 5 Most Recently Viewed Articles

Soka Gakkai International's Commitment to Peace and Dialogue

Updated Category News Views 482

Soka Gakkai International Empowers Dialogue at Peace Forum Recently, Soka Gakkai International (SGI) announced its participation in a significant event dedicated to peace and dialogue. This forum will take place following a prestigious Nobel Peace Prize ceremony where the Association of Hibakusha will receive accolades for their enduring advocacy for world peace. A Forum...

Continue Reading
Harnessing AI for Effortless Image and Video Creation with Sisi

Updated Category News Views 369

Revolutionizing Visual Content Creation with AI In an age where digital visuals play a crucial role in communication, Fotor stands out as a pioneer in enhancing creativity with technological prowess. The company has recently introduced the Fotor AI Agent, affectionately known as Sisi, an innovative AI-powered assistant geared to simplify the process of creating images and...

Continue Reading
China Hour Expands Chinese Media Footprint in Africa

Updated Category News Views 51

An Ambitious Cross-Continental Media Play The airwaves are getting a new twist. This time, it's a blend of cultures, as China Hour makes an entrance in South Africa. That's right, folks—Jiangsu Broadcasting Corporation (JSBC) has set up camp alongside the South African Broadcasting Corporation (SABC), pushing a big media wave across the continent. If you've been...

Continue Reading
BlockFills Enhances Liquidity for Institutional Traders in Crypto

Updated Category News Views 209

BlockFills Partners with CoinDesk Indices for Enhanced Market Liquidity BlockFills, a prominent player in the digital assets sector, is making strides to improve liquidity in the cryptocurrency market. Its recent collaboration with CoinDesk Indices aims to establish an institutional-grade options market, particularly targeting the CoinDesk 20 Index. This initiative is...

Continue Reading
Understanding the Recent Options Trends with Airbnb (NASDAQ: ABNB)

Updated Category News Views 101

Airbnb's Options Activity Explained Investors are eyeing Airbnb (NASDAQ: ABNB) with a fair amount of skepticism lately. Notably, there has been a noteworthy increase in bearish options activity, a trend that could indicate potential shifts in market dynamics that traders should not take lightly. Our observations reveal significant insights into how savvy players are...

Continue Reading